Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 5/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.56 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424603 | 0.85 | TP53 (0.60) | TGM2KDM4ECES1CHRM1ALDH1A1 | |
| SCHEMBL18669183 | 0.83 | GAA (0.78) | GAAKDM4ERECQLALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL9098693 | 0.83 | DRD2 (0.60) | CES1ALDH1A1ALDH3A1BCHETP53 | |
| SCHEMBL18955078 | 0.82 | CHRM5 (0.57) | TGM2CES1CHRM1ALDH1A1ALDH2 | |
| SCHEMBL18954691 | 0.81 | TGM2 (0.68) | TGM2CES1CHRM1ALDH1A1ALDH2 | |
| SCHEMBL18955090 | 0.81 | CA1 (0.69) | — | |
| SCHEMBL15928248 | 0.80 | TGM2 (0.75) | TGM2CES1CHRM1ALDH1A1ALDH2 | |
| SCHEMBL12930291 | 0.79 | CDC25A (0.56) | GAAKDM4ERECQLUSP2HSD17B10 | |
| SCHEMBL4596003 | 0.79 | CES1 (0.67) | TGM2CES1CHRM1ALDH1A1ALDH2 | |
| SCHEMBL281572 | 0.79 | TGM2 (0.57) | TGM2CES1CHRM1ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2750508-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Wayne State University (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2009123080-A1 | INDOLINONE COMPOUND | アステラス製薬株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | TGM2 4700/4885GAA 3046/4885KDM4E 3803/4885 |
| US-20110009379-A1 | INDOLINONE COMPOUND | TRPA1, TRPV1, TRPV6 | TGM2 2745/4885GAA 2363/4885KDM4E 4636/4885 |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | TGM2 2152/4885GAA 193/4885KDM4E 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.